First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-05-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-12-326322PMID 21403128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Donor cell leukemia: a review.

  2011cited by this paper
• Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia

  2009cited by this paper
• Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.

  2008cited by this paper
• Donor cell leukemia: insight into cancer stem cells and the stem cell niche.

  2007cited by this paper
• Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

  2007cited by this paper
• Donor cell leukemia: A critical review

  2007cited by this paper
• Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.

  2006cited by this paper
• Nucleophosmin and cancer

  2006cited by this paper
• Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

  2005cited by this paper
• Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).

  2005cited by this paper
• C/EBPalpha mutations in acute myeloid leukaemias.

  2004cited by this paper
• C/EBPα mutations in acute myeloid leukaemias

  2004cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• The role of FLT3 in haematopoietic malignancies

  2003cited by this paper
• The role of MLL in hematopoiesis and leukemia

  2002cited by this paper
• Two genetic hits (more or less) to cancer

  2001cited by this paper
• C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4.

  2001cited by this paper
• C/EBPα Arrests Cell Proliferation through Direct Inhibition of Cdk2 and Cdk4

  2001cited by this paper
• Leukaemic transformation of engrafted human marrow cells in vivo.

  1971cited by this paper

• A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation

  2025cites this paper
• Detecting likely germline variants during tumor-based molecular profiling

  2025cites this paper
• Allogeneic Transplantation for Older Adults.

  2025cites this paper
• CEBPA-associated familial acute myeloid leukemia mimicking Werner syndrome: a case report

  2025cites this paper
• Genetic Predisposition to Hematologic Malignancies.

  2025cites this paper
• Capture‐based targeted sequencing using a T‐cell control in myeloid malignancies and idiopathic cytopenias

  2024cites this paper
• Genomic testing for germline predisposition to hematologic malignancies

  2024cites this paper
• Genomic profiling of pediatric hematologic malignancies and diagnosis of cancer predisposition syndromes: tumor-only versus paired tumor-normal sequencing

  2024cites this paper
• Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders.

  2024cites this paper
• Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome

  2024cites this paper
• Clinical features and management of germline CEBPA-mutated carriers.

  2024cites this paper
• Risk assessment and genetic counseling for hematologic malignancies—Practice resource of the National Society of Genetic Counselors

  2024cites this paper
• The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

  2024cites this paper
• Germline Predisposition to Hematopoietic Malignancies: An Overview

  2024cites this paper
• Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia

  2024cites this paper
• Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy

  2023cites this paper
• Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era.

  2023cites this paper
• Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT.

  2023cites this paper
• Germline Predisposition to Myeloid Neoplasms: Diagnostic Concepts and Classifications.

  2023cites this paper
• How I diagnose myeloid neoplasms with germline predisposition.

  2023cites this paper
• Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations

  2023cites this paper
• A case of donor cell leukemia driven by a de novo NRAS mutation with complex karyotype

  2023cites this paper
• Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants

  2023cites this paper
• International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

  2022cites this paper
• The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia

  2022cites this paper
• Germline predisposition variants occur in myelodysplastic syndrome patients of all ages.

  2022cites this paper
• CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition

  2022cites this paper
• Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome

  2021cites this paper
• Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer

  2021cites this paper
• Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology.

  2021cites this paper
• Novel insights of acute myeloid leukemia with CEBPA deregulation: heterogeneity dissection and re-stratification.

  2021cites this paper
• Sibling donor-derived myeloid sarcoma after hematopoietic stem cell transplant

  2021cites this paper
• Germline Predisposition in AML

  2021cites this paper
• Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients.

  2021cites this paper
• Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges

  2021cites this paper
• Aetiology of MDS: With a Focus on Hereditary Predisposition

  2021cites this paper
• Germline Predisposition to Myeloid Neoplasms in Inherited Bone Marrow Failure Syndromes, Inherited Thrombocytopenias, Myelodysplastic Syndromes and Acute Myeloid Leukemia: Diagnosis and Progression to Malignancy

  2021cites this paper
• Identifying potential germline variants from sequencing hematopoietic malignancies.

  2020cites this paper
• Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia

  2020cites this paper
• Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

  2020cites this paper
• AML through the prism of molecular genetics

  2020cites this paper
• Stem cell donors should be screened for CHIP.

  2020cites this paper
• A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance

  2020cites this paper
• The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

  2020cites this paper
• Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation

  2020cites this paper
• Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities

  2020cites this paper
• Identifying potential germline variants from sequencing hematopoietic malignancies.

  2020cites this paper
• When should transplant physicians think about familial blood cancers?

  2019cites this paper
• Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia

  2019cites this paper
• Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia

  2019cites this paper
• ETV6-Related Thrombocytopenia and Leukemia Predisposition.

  2019cites this paper
• Somatic mutation panels: Time to clear their names.

  2019cites this paper
• PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia

  2018cites this paper
• Donor Cell-Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review.

  2018cites this paper
• Myeloid Neoplasm With Germline Predisposition: A 2016 Update for Pathologists.

  2018cites this paper
• Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?

  2018cites this paper
• Donor-derived MDS/AML in families with germline GATA2 mutation.

  2018cites this paper
• Inherited predisposition to MDS/AML

  2018cites this paper
• Donor Qualification for Hematopoietic Cell Transplantation

  2018cites this paper
• Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement

  2018cites this paper
• Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience

  2017cites this paper
• Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation.

  2017cites this paper
• Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients

  2017cites this paper
• Familial CEBPA-mutated acute myeloid leukemia.

  2017cites this paper
• Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults

  2016cites this paper
• How I diagnose and manage individuals at risk for inherited myeloid malignancies.

  2016cites this paper
• Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang

  2016cites this paper
• Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation

  2016cites this paper
• Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation

  2016cites this paper
• Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.

  2016cites this paper
• Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)

  2015cites this paper
• Donor lymphocytes may acquire cytolytic specificity to donor's engrafted hematopoietic cells after a hematopoietic stem cell allograft resulting in marrow failure.

  2014cites this paper
• Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia.

  2013influential citation
• Versatility and nuances of the architecture of haematopoiesis - Implications for the nature of leukaemia.

  2012cites this paper
• The versatile landscape of haematopoiesis: Are leukaemia stem cells as versatile?

  2012cites this paper
• Update on cytogenetic and molecular changes in myelodysplastic syndromes

  2012cites this paper
• Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

  2012cites this paper
• Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms

  2011cites this paper